Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

Featured

Conference Coverage
AHA
Conference Coverage
AI-ECG and AI-Echo Flag Unrecognized ATTR-CM Risk
11/10/2026
Brian McCurdy
A retrospective US analysis found AI-ECG and AI-Echo identified probable ATTR-CM in adults aged 50–95, with dual-positive screens associated with higher mortality.
11/10/2026
Conference Coverage
AHA
Conference Coverage
Genetic Testing Reaches Only 60% of ATTR-CM Patients, With Tests Declining With Age
11/10/2026
Brian McCurdy
A retrospective study of 164 patients receiving disease-modifying therapy for ATTR-CM found genetic testing declined with age; 27.3% of tested patients had pathogenic TTR variants.
11/10/2026
Conference Coverage
AHA
Conference Coverage
LLM Pipeline Flags 218 Untreated Patients With Suspected ATTR-CA
11/10/2026
Brian McCurdy
An LLM chart-review study of 24,080 adults identified 218 untreated patients with suspected ATTR-CA and incomplete evaluations, most lacking a PYP order.
11/10/2026

Interactive Features

3-in-30
illustration of open book
3-in-30
3-in-30: Recognizing Trends in ATTR-CM
10/12/2026
Anthony Calabro, MA
Recent US claims data offer insight into how transthyretin amyloid cardiomyopathy’s diagnosed incidence, prevalence, and associated clinical burden have changed over time.
10/12/2026

Clinical Insights

ACC.25 Video Interview
Rachel Lampert, MD
ACC.25 Video Interview
ACC.25 Presentation—Arrhythmias in Athletes: Management and Return to Play
04/15/2025
Rachel Lampert, MD
In this video, Rachel Lampert, MD, Robert W. Berliner Professor of Internal Medicine at the Yale School of Medicine, reviews her presentation at the American College of Cardiology 2025 Annual Meeting,...
04/15/2025